Fig. 2: Characterization of NLG-HKD and Abe-NF(g). | Nature Communications

Fig. 2: Characterization of NLG-HKD and Abe-NF(g).

From: Injectable supramolecular hydrogel co-loading abemaciclib/NLG919 for neoadjuvant immunotherapy of triple-negative breast cancer

Fig. 2

a The synthesis scheme of the peptide-drug conjugate NLG-HKD. b Cumulative release of NLG919 from NLG-HKD in PBS or 10 mM GSH (n = 3 independent experiments). c, d Critical micelle concentration (c) and the representative cryo-TEM image (d) of NLG-HKD. e Photographs and cryo-TEM images of the Abe-NF(g) at different pH values with or without PBS. d–e Scale bars = 200 nm. f–g Frequency sweeps of G′ and G′′ of Abe-NF(g) at the absence (f) and presence (g) of salts before or after injection. The experiments were performed at 25 °C with a strain of 0.5%. h ζ-potentials of Abe-CF, NF, and Abe-NF (n = 3 independent experiments). i Abe release profile from the Abe-NF(g) in PBS (n = 3 independent experiments). The Abe solution was used as a control group. Data were presented as mean ± SD. PBS phosphate-buffered saline, DMSO dimethyl sulfoxide, DIC diisopropylcarbodiimide, DIPEA diisopropylethylamine, GSH glutathione, Abe abemaciclib. Source data are provided as a Source Data file.

Back to article page